Loading organizations...
§ Venture Capital · Beijing, China
Life sciences investment fund providing private equity capital and strategic guidance for healthcare companies in China and the U.S.
BVCF (BioVeda China Fund) is a private equity firm established in 2005 by founder Zhi Yang as the first US dollar-denominated fund focused on healthcare investments in China. The firm invests in life sciences companies operating across China and the United States, providing capital and strategic guidance to businesses spanning the pharmaceuticals, genomics, medical devices, and biotechnology sectors. Throughout its history, the fund has built a diverse portfolio of over 30 companies and achieved eight documented exits, which include four initial public offerings and four corporate acquisitions. The leadership team features partner Robert Li, who joined in 2007 and brings expertise from prior roles connected to major industry entities like Human Genome Sciences. This background is notable within the life sciences sector, as Human Genome Sciences was ultimately acquired by GSK for $3 billion.
Key people at BVCF (Bioveda China Fund).
BVCF (Bioveda China Fund) has 4 tracked investments across 4 companies. The latest tracked deal is $15.0M Series A in Cellenkos in November 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2021 | Cellenkos | $15.0M Series A | Bvcf (bioveda China Fund) | — |
| May 1, 2021 | Oculis | $57.0M Series C | Bvcf (bioveda China Fund), DR. Sylvia XIN HE | ZHI Yang, Kiersten Stead, Dimension Capital, Earlybird Venture Capital, Eclipse Ventures, EQT Life Sciences, Longitude Capital, Maveron, NEW Enterprise Associates (NEA), OrbiMed, Peterson Ventures, Pivotal BioVenture Partners, The Column Group, Farzad Nazem, BAY City Capital, Brunnur Ventures, NAN Fung Life Sciences, Novartis, Silfurberg, Tekla Capital Management, VI Partners, Wille Finance |
| Jan 1, 2015 | DiaCarta | $8.0M Series A | Bvcf (bioveda China Fund) | — |
| Feb 1, 2014 | Jaguar Health | $7.0M Series A | Bvcf (bioveda China Fund) | — |
Key people at BVCF (Bioveda China Fund).
BVCF (BioVeda China Fund) is a specialist investment firm focused on providing growth capital to China-based companies primarily in the life sciences and healthcare sectors, including biotech, healthtech, medical devices, and healthcare services. Its mission centers on fostering innovative global Chinese life sciences companies to improve health outcomes and generate wealth worldwide. BVCF supports companies that address critical healthcare challenges, helping them scale and commercialize their technologies, thereby impacting the startup ecosystem by bridging capital and expertise to a rapidly evolving Chinese healthcare market[1][2][3].
Founded in 2005, BVCF was the first US dollar-denominated fund dedicated to investing in healthcare companies in China. The firm was established by Dr. Zhi Yang, a former scientist, who remains a key partner and managing figure. Over time, BVCF has evolved to become a seasoned pioneer in healthcare investment management in China, expanding its focus to include a broad range of life sciences and healthcare growth companies. The fund has attracted global institutional investors, including development finance institutions like IFC and SIFEM, reflecting its credibility and strategic importance[3][4][5].
BVCF rides the global trend of increasing investment in healthcare innovation, particularly within China’s rapidly growing life sciences market. The timing is critical as China’s healthcare system modernizes and demand for advanced medical technologies surges. Market forces such as government support for biotech innovation, rising healthcare spending, and a growing middle class fuel this momentum. BVCF influences the ecosystem by channeling international capital and expertise into Chinese startups, accelerating their growth and integration into global healthcare markets[1][3][4].
Looking ahead, BVCF is poised to continue leveraging its scientific leadership and global network to capitalize on emerging trends like precision medicine, digital health, and advanced medical devices in China. As regulatory frameworks evolve and innovation accelerates, BVCF’s role as a bridge between global investors and Chinese healthcare innovators will likely deepen. Its influence may expand beyond capital provision to shaping strategic partnerships and fostering cross-border collaborations, reinforcing its position as a key player in the global life sciences investment landscape[3][4][5].
